Neurocrine Biosciences 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Neurocrine Biosciences reported record third-quarter 2026 net product sales of more than $1.1 billion, up more than 40% year over year, and record operating profitability.
- Ingreza sales were $801 million, up 17% year over year; the quarter included a $20 million benefit from customer order timing, expected to reverse in the fourth quarter.
- Quinacidy sales were $211 million, and Vicod XR sales were $107 million; both products reached record quarterly sales levels.
- The company ended the quarter with approximately $800 million in cash, generated $400 million in operating cash flow, and deployed approximately $100 million to repurchase shares and offset dilution from share-based compensation.
- Management said it initiated a phase two study of NBI 567 in Alzheimer's disease and a phase one study of NVIP 1968 in obesity; NBI 223 is expected to enter phase one in the coming months, with initial patient-level data anticipated in 2027.
- Neurocrine remains on track to deliver six phase ones and five new phase two starts this year, which management described as the highest level of R&D productivity in the company's 35-year history.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Thank you for your continued patience. Your meeting will begin shortly. If you need assistance at any time, please press star 0, and a member of our team will be happy to help you. Please stand by. Your meeting is about to begin. Hello, and welcome everyone joining today's Neurocrine Biosciences Third Quarter 2026 Earnings Call. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. To register to ask a question at any time, please press star 1 on your telephone keypad. We ask that please limit yourself to one question. Please note this call is being recorded, and we are standing by if you should need any assistance. It is now my pleasure to turn the meeting over to Todd Tushla, Vice President of Investor Relations. Please go ahead. Thank you, and happy Monday wherever it is that you may be.
Welcome to Neurocrine Biosciences Third Quarter 2026 Earnings Call. Joining me on today's call are Kyle Gano, Chief Executive Officer, Matt Abernethy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, Eiry Roberts, Chief Medical Officer, and Samir Siddhanti, Chief Business Officer. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. In addition, some of the information discussed today includes non-GAAP financial measures that have not been calculated in accordance with U.S. GAAP. Reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures are presented in the tables at the end of our earnings release issued earlier today, which has been posted on the Investor Relations page of the company's website.
Following prepared remarks, we'll be happy to take your questions. With that, I'll hand the call off to Kyle.
Good afternoon, everyone. Nearly two years ago, on my first earnings call as CEO, I shared my optimism about Neurocrine's future and the significant opportunities ahead. Today, that confidence has only grown stronger as I remain deeply confident in our ability to drive sustained growth and create long-term value for our shareholders. Our strategy to build a leading biopharmaceutical company is grounded in execution and delivering meaningful results. In the third quarter, we generated record net product sales of more than $1.1 billion and record profitability. These results underscore the strength of our diversified portfolio of three first-in-class medicines and our growing ability to reach and serve more patients than ever before. This momentum positions us well to drive continued growth across INGREZZA, CRENESSITY, and VYKAT XR in 2027 and beyond.
The strength of our growing commercial business and financial position also enables us to continue investing in our industry-leading pipeline. With several important clinical milestones anticipated in 2027, including phase III data readouts for osavampator in major depressive disorder and direclidine in schizophrenia, we believe Neurocrine is approaching a potentially transformative period, one that could further expand our pipeline, strengthen our long-term growth prospects, and extend our impact on patients. Overall, Neurocrine's third quarter performance exemplifies the strength of our strategy, the discipline of our execution, and the significant opportunity ahead to create long-term value. As we close out the year, we look forward to hosting our 2026 R&D Day in New York City on December 15.
The event will feature a VYKAT XR panel discussion with Dr. Jennifer Miller, Professor of Pediatric Endocrinology and Director of the Prader-Willi Syndrome Program at the University of Florida College of Medicine, as well as an update on our pipeline. I look forward to sharing our progress, engaging with the investment community, and discussing the opportunities ahead as we enter what promises to be a catalyst-rich 2027. With that, I'll turn the call over to Matt.
Thank you, Kyle, and good afternoon, everyone. The third quarter reflects Neurocrine's continued evolution into a diversified, highly profitable biopharmaceutical company. As Kyle mentioned, we delivered record net product sales exceeding $1.1 billion, up more than 40% year-over-year, alongside record operating profitability. Our three commercial products provide a growing foundation to invest in innovation and prepare for a data-rich 2027. Starting with INGREZZA, third quarter sales were $801 million, up 17% year-over-year, driven by continued volume growth with record new and total prescriptions. Underlying INGREZZA performance continues to exceed our own internal expectations, leading to another full-year INGREZZA guidance increase to $2.9 billion-$2.925 billion. Third quarter sales included a $20 million benefit from customer order timing, which we expect to reverse in the fourth quarter and is reflected in our full-year guidance.
Overall, 2026 is turning out to be a remarkable year for INGREZZA, with prescription growth expected to be in the high teens, underscoring the strength and durability of the INGREZZA franchise in the tardive dyskinesia market. Looking ahead to 2027, we expect continued double-digit INGREZZA volume growth to more than offset anticipated mid- to high single-digit net pricing headwinds, supporting another year of revenue growth. As customary, we will provide formal 2027 sales guidance in February. CRENESSITY delivered $211 million in third quarter sales, supported by steady patient additions, strong persistency, and favorable reimbursement. Over 15% of the estimated diagnosed classic CAH population has now been prescribed CRENESSITY, highlighting the opportunity that we still have ahead. For VYKAT XR, we delivered $107 million in third quarter sales, reflecting sequential growth driven by new patient demand.
We remain focused on our efforts to support appropriate patient identification, physician and caregiver education, and patient support. We believe VYKAT XR offers a meaningful opportunity for long-term growth to help many patients with this devastating condition. Turning to the financials, record revenue drove non-GAAP earnings above $3 per share. This reflects significant operating leverage while continuing to invest in commercial growth and our R&D pipeline. We ended the quarter with approximately $800 million in cash, generating $400 million in operating cash flow and deploying approximately $100 million to repurchase shares and offset dilution from our share-based compensation. Our capital allocation priorities remain driving commercial growth, advancing high-value pipeline programs, and pursuing disciplined business development. Overall, with three growing commercial products, expanding profitability, and a broad pipeline, Neurocrine is well-positioned for durable growth and important clinical catalysts in 2027.
With that, I'll turn the call over to Eric Benevich, our Chief Commercial Officer. Eric? Thanks, Matt. Our record third quarter performance reflects strong performance across all three of our first-in-class medicines: INGREZZA, CRENESSITY, and VYKAT XR.
While each is at a different stage of commercialization, all three continue to address significant unmet medical needs and contribute to Neurocrine's commercial diversification and revenue growth. Starting with INGREZZA, quarterly sales surpassed $800 million for the first time, driven by strong demand with record new and total prescriptions. Remarkably, nine years into launch, INGREZZA continues to deliver double-digit prescription growth. With full-year sales guidance raised once again, 2026 is shaping up to be another outstanding year for the brand. CRENESSITY also reached a new milestone, exceeding $200 million in quarterly sales for the first time. The rate of new patient starts have remained steady throughout the year, and we estimate more than 15% of U.S. patients with classic congenital adrenal hyperplasia have now been prescribed CRENESSITY.
Just seven quarters into the launch, we're making meaningful progress towards establishing CRENESSITY together with low-dose GCs as the standard of care treatment for classic CAH. Now, turning to VYKAT XR, quarterly sales exceeded $100 million for the first time. Since the acquisition, our commercial and medical teams have focused on HCP education, including appropriate PWS patient selection, dose titration, careful monitoring, and management of potential adverse events while setting expectations for both the timing and nature of treatment response. These efforts reflect our commitment to maximizing patient safety and treatment results. As newcomers to the PWS community, we're listening to all stakeholders and gaining insights from clinicians, PWS scientific thought leaders, and the Prader-Willi syndrome patient and family community. We're confident in VYKAT XR's benefit and its longer-term potential in our rare endocrine franchise.
2026 will no doubt end up being the strongest commercial year in Neurocrine's history, and we look forward to carrying this momentum into 2027. I want to thank our entire commercial and medical organizations, including our newest VYKAT XR colleagues, for their unwavering dedication to patients and outstanding execution. With that, it's my pleasure to turn the call over to our Chief Medical Officer, Dr. Eiry Roberts.
Thanks, Eric, and good afternoon, everyone. First, I want to thank Kyle and the board of directors for the opportunity to return as Chief Medical Officer. During my previous tenure, I had the privilege of helping advance CRENESSITY through clinical development and approval, as well as generating positive phase II data and initiating the phase III programs for both osavampator and direclidine. I'm excited to build upon the team's recent progress as we advance the deepest and most diversified pipeline in Neurocrine's history. I'd like to begin today with VYKAT XR, the first and only FDA-approved treatment for hyperphagia in patients age 4 and older with Prader-Willi syndrome. Since Neurocrine's acquisition of this medicine in May, our clinical and medical teams have worked closely with expert clinicians, regulators, and the PWS community to support the safe and appropriate use of this important new medicine.
As real-world experience grows, we remain committed to ongoing safety monitoring, collaboration with the FDA, and timely communication of important new information. To further advance our understanding, we plan to initiate a study in 2027 evaluating VYKAT XR in people with PWS and complex health issues. Continued engagement with advocacy organizations, including FPWR and PWSA USA, remains central to our efforts also. Turning to the pipeline, we recently initiated a phase II study of NBI-567, our M1-preferring selective muscarinic agonist, as an adjunctive treatment for cognition in Alzheimer's disease. In obesity, we initiated a phase I study of NBIP-1968, our investigational triple G agonist. This program has the potential to complement our CRF2 agonist, NBIP-2118, also in phase I, as we explore differentiated combinations to treat obesity.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
31 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
